Izalontamab

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 10:15:55 GMT 2025` Edited by `admin` on `Wed Apr 02 10:15:55 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	S8YH2C9NLA
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Izalontamab

Official Name

English

SI-B001

Preferred Name

English

IZALONTAMAB [USAN]

Common Name

English

Izalontamab [WHO-DD]

Common Name

English

Anti-EGFR/HER3 Bispecific Antibody SI-B001

Common Name

English

Immunoglobulin G1-scFv_L-kappa dimer, anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)] and anti-[Homo sapiens ERBB3 (receptor tyrosine protein kinase erbB-3, HER3)], monoclonal

Common Name

English

HER3 x EGFR SI-B001

Common Name

English

izalontamab [INN]

Common Name

English

Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (hum

Common Name

English

Code System Code Type Description

SMS_ID

300000043879

Created by admin on Wed Apr 02 10:15:55 GMT 2025 , Edited by admin on Wed Apr 02 10:15:55 GMT 2025

PRIMARY

USAN

MN-273

Created by admin on Wed Apr 02 10:15:55 GMT 2025 , Edited by admin on Wed Apr 02 10:15:55 GMT 2025

PRIMARY

CAS

2559704-24-2

Created by admin on Wed Apr 02 10:15:55 GMT 2025 , Edited by admin on Wed Apr 02 10:15:55 GMT 2025

PRIMARY

NCI_THESAURUS

C178396

Created by admin on Wed Apr 02 10:15:55 GMT 2025 , Edited by admin on Wed Apr 02 10:15:55 GMT 2025

PRIMARY

FDA UNII

S8YH2C9NLA

Created by admin on Wed Apr 02 10:15:55 GMT 2025 , Edited by admin on Wed Apr 02 10:15:55 GMT 2025

PRIMARY

INN

12022

Created by admin on Wed Apr 02 10:15:55 GMT 2025 , Edited by admin on Wed Apr 02 10:15:55 GMT 2025

PRIMARY

From	To
4_134	4_194
4_23	4_88
3_134	3_194
3_23	3_88
1_231	2_231
1_228	2_228
2_222	4_214
1_222	3_214
1_613	1_681
2_613	2_681
1_480	1_554
2_480	2_554
1_369	1_427
2_369	2_427
1_263	1_323
2_263	2_323
1_146	1_202
2_146	2_202
1_22	1_95
2_22	2_95

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_88
N	1_299
N	2_88
N	2_299

Related Record Type Details


					RSO83C9PIA

RECEPTOR TYROSINE-PROTEIN KINASE ERBB-3

TARGET -> INHIBITOR

Amount:


					RO03J093CP

EPIDERMAL GROWTH FACTOR RECEPTOR

TARGET -> INHIBITOR

Amount:


					UC2FX6YY3P

Izalontamab Brengitecan

CONJUGATE -> PARENT

Amount:

Related Record Type Details


					S8YH2C9NLA

ACTIVE MOIETY

Comments:

antineoplastic

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL